PTCT PTC THERAPEUTICS, INC. Insider Trading

Director Mary L. Smith sold 15,834 shares at $90.00 ($1.4M) under pre-arranged 10b5-1 plan at PTCT

Director Mary L. Smith executed 2 separate sales totaling 15,834 shares (15.8K shares) for $1,425,060.00 ($1.4M) at $90.00 on 2026-07-09 under a pre-arranged 10b5-1 trading plan adopted 2025-11-11, reducing her holdings from 37,647 shares to 21,813 shares. The sale occurred near the 52-week high of $90.87, with the stock currently trading at $81.33 (-10.5% from that high). This is a scheduled, non-discretionary transaction under the 10b5-1 framework, so no inference about conviction or market timing should be drawn from the execution date itself. The company posted net losses of $-2.8M in the latest quarter, though annual revenue growth reached +114.5%, creating mixed fundamental signals that the filing alone cannot resolve.

Chief Technical Ops Officer Neil Gregory Almstead sells 46,774 shares (43.7% of pre-transaction holdings) for $4,093,481.61 via 8 transactions on 2026-07-06/07

Neil Gregory Almstead executed 8 separate sales totaling 46,774 shares for $4,093,481.61 across July 6–7, 2026, reducing his non-derivative holdings from 107,073 to 60,299 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, making it a scheduled sale rather than a discretionary trade. The blended average price of $87.52 compares closely to the current price of $88.57 and sits near the 52-week high of $89.85. PTCT's fundamentals show revenue growth of +114.5% year-over-year alongside a net loss of $-2,809,000 in the latest quarter, reflecting a high-growth biotech profile. The insider retains 61,615 derivative securities (stock options) across four vehicles, preserving significant upside exposure while harvesting proceeds from the non-derivative tranche. The cross-ticker track record shows negative average 90-day returns of -7.1% following prior sales, though this transaction's scheduled nature removes timing as an interpretive factor.

Chief Technical Ops Officer Neil Gregory Almstead sold 26,283 shares (26.3K shares) for $2,254,463.35 ($2.3M) via 7 transactions at PTCT, per 10b5-1 plan

Neil Gregory Almstead, Chief Technical Ops Officer, executed 7 separate sales totaling 26,283 shares for $2,254,463.35 on 2026-06-24 and 2026-06-25 at an average price of $85.78, reducing non-derivative holdings by 30.4% to 60,137 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, meaning the sales were scheduled and not discretionary. Almstead retains 213,919 shares in derivative holdings (stock options) across five tranches, preserving meaningful future upside exposure. His prior PTCT-specific sales (5 trades dating to late 2025 and early 2026) showed modest negative returns in the 30-day and 90-day periods post-sale, with 90-day outcomes ranging from -15.5% to -16.7% when measured. The stock currently trades at $84.43, down 3.5% from its 52-week high of $87.50 and up 19.5% over the prior 30 days and 27.7% over the prior 90 days, reflecting recent positive momentum. PTCT's fundamentals show strong annual revenue growth of 114.5%, though the company is currently unprofitable with a net loss of $2,809,000 on revenue of $272,551,000.

Neil Gregory Almstead (CTO) sold 23,749 shares at $80.90 avg for $1.9M via scheduled 10b5-1 plan

Neil Gregory Almstead, Chief Technical Operations Officer, executed 2 separate sales totaling 23,749 shares for $1,921,378.29 on 2026-06-22 pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-11-11. His non-derivative holdings decreased 28.3% from 83,886 shares to 60,137 shares; however, he retains 23,751 stock options (derivative securities) in Table II. The stock has appreciated +22.7% over 30 days and +26.0% over 90 days, currently trading at $84.41, which is -3.5% from its 52-week high of $87.50. At PTCT specifically, his prior 5 open-market trades show 30-day returns ranging from -7.4% to -5.4%, with the two measurable 90-day outcomes at -16.7% and -15.5%. This transaction is scheduled, not discretionary, under the 10b5-1 framework.

SVP/Chief Accounting Officer Christine Marie Utter sold 19,686 shares of PTCT at $75.56 under pre-arranged 10b5-1 plan; retains 70,199 shares plus 15,314 stock options

Christine Marie Utter, Chief Accounting Officer, sold 19,686 shares (19.7K shares) for $1,487,474.16 ($1.5M) on 2026-06-17 at $75.56 as part of a scheduled 10b5-1 trading plan adopted 2026-03-17. The stock has since risen to $80.96 (current price), though remains -7.5% from its 52-week high of $87.50. Post-transaction, Utter retains 70,199 non-derivative shares plus 15,314 shares through stock options, indicating a partial reduction rather than an exit. PTCT has delivered substantial growth: annual revenue increased 114.5% year-over-year to $272.6M in the latest quarter, though the company reported a net loss of $2.8M. The scheduled nature of this sale—locked in via pre-arranged plan three months prior to execution—removes discretionary timing as a signal; investors should focus on the company's operating fundamentals (strong topline growth offset by current-quarter profitability challenges) rather than on the insider's trade timing or conviction.

PTC CLO Mark Elliott Boulding sold 10,462 shares for $822,867.75 in 4 scheduled transactions on 2026-06-17 under 10b5-1 plan.

Mark Elliott Boulding, Executive VP and CLO, executed 4 separate sales totaling 10,462 shares for $822,867.75 on 2026-06-17 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-10, reducing his non-derivative holdings from 115,734 to 105,272 shares. The sales occurred at blended average price of $78.65, while current market price stands at $80.96; however, this is a scheduled, non-discretionary transaction plan, so transaction timing is not a discretionary variable. PTCT's fundamentals show strong revenue growth of +114.5% year-over-year against latest quarterly revenue of $272,551,000.00, though the company reported net loss of $-2,809,000.00 for the latest quarter. Boulding retains 63,888 derivative shares (stock options) across two vehicles, maintaining significant equity exposure to the company.

PTC Therapeutics CBO Eric Pauwels sells 21.3K shares at $75.00 for $1.6M under 10b5-1 plan

Eric Pauwels, Chief Business Officer of PTC Therapeutics, Inc., executed 2 separate sales totaling 21,277 shares for $1,595,775.00 at $75.00 per share on 2026-06-10 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25. Following this scheduled transaction, Pauwels retains 73,411 shares in non-derivative holdings, representing a -22.5% reduction from his pre-transaction position of 94,688 shares. The company reported revenue of $272,551,000.00 in its latest quarter with net income of $-2,809,000.00, and the stock currently trades at $75.14, within its 52-week range of $43.18–$87.50. Across his prior 5 sales at this same ticker, the 90-day returns after sale ranged from -14.4% to -11.4%, establishing a measurable historical pattern at this security.

CEO Klein sells 10,000 shares (10.0K) for $730,786.42 via scheduled 10b5-1 plan

Matthew B. Klein, CEO of PTC Therapeutics, executed three separate sales totaling 10,000 shares for $730,786.42 on 2026-05-14 at a blended average price of $73.08, reducing his holdings by 2.5% from 406.6K to 396.6K shares. This transaction was part of a pre-arranged 10b5-1 trading plan, making it scheduled rather than discretionary. The stock currently trades at $71.47, -18.3% from its 52-week high of $87.50, suggesting the sales occurred in a relative strength period. Examining Klein's same-ticker history at PTCT shows a pattern of prior sales, though without forward-looking detail on execution discretion, the scheduled plan nature means timing considerations do not apply to this filing itself.

PTC Chief Technical Ops Officer Neil Gregory sells 52,003 shares for $3.6M via 10b5-1 plan

Neil Gregory, Chief Technical Operations Officer, executed 3 separate sales totaling 52,003 shares for $3,590,242.77 at a blended average price of $69.04 on 2026-04-01. This transaction reduced his holdings by 46.4%, from 112,140 shares to 60,137 shares post-transaction. The sales were conducted pursuant to a 10b5-1 trading plan adopted on 2025-11-11, indicating these were scheduled, non-discretionary transactions rather than discretionary trades responsive to current market conditions. While the substantial reduction in personal shareholding is notable from a stake-size perspective, the pre-arranged plan structure removes any inference about current timing decisions or conviction regarding the stock's near-term direction.

Director Okey Stephanie sells 15,167 shares for $1,061,690.00 under pre-arranged 10b5-1 plan

Okey Stephanie, a director at PTC Therapeutics, executed 2 separate sales totaling 15,167 shares for $1,061,690.00 on 2026-03-10, reducing her holdings from 23,167 shares to 8,000 shares. This represents a 65.5% reduction in her post-transaction holdings. The transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, meaning it was scheduled and not discretionary. While the magnitude of the reduction is substantial, the pre-arranged nature of the sale limits what can be inferred about director confidence or market timing from this particular filing alone. Investors should monitor whether additional scheduled sales follow under the same plan.